A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS≤25 (RxFINE-Low)
Read more about this trial →← Back to available clinical trials
A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS≤25 (RxFINE-Low)
Read more about this trial →